Skip to main content

Anal Canal Cloacogenic Carcinoma clinical trials at UC Davis

1 research study open to eligible people

Showing trials for
  • A Study of Experimental Nivolumab After Combined Modality Therapy For High Risk Stage II-IIIB Anal Cancer

    open to eligible people ages 18 years and up

    This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    Sacramento, California and other locations

Last updated: